NO20072601L - Azaindolkarboksamider - Google Patents
AzaindolkarboksamiderInfo
- Publication number
- NO20072601L NO20072601L NO20072601A NO20072601A NO20072601L NO 20072601 L NO20072601 L NO 20072601L NO 20072601 A NO20072601 A NO 20072601A NO 20072601 A NO20072601 A NO 20072601A NO 20072601 L NO20072601 L NO 20072601L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- azaindolkarboksamider
- ht1a
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004054634A DE102004054634A1 (de) | 2004-11-12 | 2004-11-12 | Azaindolcarboxamide |
| PCT/EP2005/012127 WO2006050976A1 (de) | 2004-11-12 | 2005-11-11 | Azaindolcarboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072601L true NO20072601L (no) | 2007-05-22 |
Family
ID=35929547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072601A NO20072601L (no) | 2004-11-12 | 2007-05-22 | Azaindolkarboksamider |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070299091A1 (es) |
| EP (1) | EP1771448A1 (es) |
| JP (1) | JP2008519797A (es) |
| KR (1) | KR20070083843A (es) |
| CN (1) | CN101056878A (es) |
| AU (1) | AU2005303904A1 (es) |
| BR (1) | BRPI0517846A (es) |
| CA (1) | CA2575668A1 (es) |
| DE (1) | DE102004054634A1 (es) |
| EA (1) | EA200700909A1 (es) |
| IL (1) | IL180317A0 (es) |
| MX (1) | MX2007005649A (es) |
| NO (1) | NO20072601L (es) |
| WO (1) | WO2006050976A1 (es) |
| ZA (1) | ZA200700252B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| AU2007354861B2 (en) * | 2007-06-15 | 2013-03-21 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use |
| WO2011082273A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
| EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| KR20150119370A (ko) | 2013-02-19 | 2015-10-23 | 화이자 인코포레이티드 | Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물 |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US10131669B2 (en) | 2014-07-24 | 2018-11-20 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| BR112017001334A2 (pt) | 2014-08-06 | 2017-11-14 | Pfizer | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende |
| MX2018001073A (es) | 2015-08-06 | 2018-06-12 | Chimerix Inc | Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales. |
| CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| US11299476B2 (en) | 2016-03-14 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof |
| WO2018021447A1 (ja) | 2016-07-28 | 2018-02-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物 |
| CN106279071B (zh) * | 2016-08-10 | 2019-01-04 | 广东东阳光药业有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| EP3684771A1 (en) | 2017-09-21 | 2020-07-29 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF |
| WO2019146739A1 (ja) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する縮環化合物 |
| JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| EP3849963A1 (en) | 2018-09-11 | 2021-07-21 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Dopamine d3 receptor selective antagonists/partial agonists and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL90279A (en) * | 1988-05-24 | 1995-03-30 | American Home Prod | History of piperazinyl carboxamide, their preparation and the pharmaceutical preparations containing them |
| ES2027898A6 (es) * | 1991-01-24 | 1992-06-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina. |
| WO1994020497A1 (en) * | 1993-03-01 | 1994-09-15 | Merck Sharp & Dohme Limited | Pyrrolo-pyridine derivatives |
| HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| RU2320656C2 (ru) * | 2002-07-04 | 2008-03-27 | Шварц Фарма Аг | Производные гетероаренкарбоксамида, способ их получения, фармацевтическая композиция на их основе и применение |
| US7605259B2 (en) * | 2002-09-14 | 2009-10-20 | University Of North Texas Health Science Center At Fort Worth | Structurally rigid dopamine d3 receptor selective ligands and process for making them |
| JP2004123562A (ja) * | 2002-09-30 | 2004-04-22 | Japan Science & Technology Corp | 神経細胞死抑制作用を有する化合物を用いた医薬 |
| BRPI0410445B1 (pt) * | 2003-05-21 | 2017-11-28 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds |
| SE0401655D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
-
2004
- 2004-11-12 DE DE102004054634A patent/DE102004054634A1/de not_active Ceased
-
2005
- 2005-11-11 BR BRPI0517846-0A patent/BRPI0517846A/pt not_active IP Right Cessation
- 2005-11-11 MX MX2007005649A patent/MX2007005649A/es not_active Application Discontinuation
- 2005-11-11 CA CA002575668A patent/CA2575668A1/en not_active Abandoned
- 2005-11-11 WO PCT/EP2005/012127 patent/WO2006050976A1/de active Application Filing
- 2005-11-11 JP JP2007540597A patent/JP2008519797A/ja active Pending
- 2005-11-11 EA EA200700909A patent/EA200700909A1/ru unknown
- 2005-11-11 AU AU2005303904A patent/AU2005303904A1/en not_active Abandoned
- 2005-11-11 EP EP05805690A patent/EP1771448A1/de not_active Withdrawn
- 2005-11-11 KR KR1020077009695A patent/KR20070083843A/ko not_active Application Discontinuation
- 2005-11-11 US US11/667,601 patent/US20070299091A1/en not_active Abandoned
- 2005-11-11 CN CNA2005800387992A patent/CN101056878A/zh active Pending
-
2006
- 2006-12-25 IL IL180317A patent/IL180317A0/en unknown
-
2007
- 2007-01-09 ZA ZA200700252A patent/ZA200700252B/xx unknown
- 2007-05-22 NO NO20072601A patent/NO20072601L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101056878A (zh) | 2007-10-17 |
| EP1771448A1 (de) | 2007-04-11 |
| KR20070083843A (ko) | 2007-08-24 |
| BRPI0517846A (pt) | 2008-10-21 |
| US20070299091A1 (en) | 2007-12-27 |
| WO2006050976A1 (de) | 2006-05-18 |
| IL180317A0 (en) | 2007-06-03 |
| AU2005303904A1 (en) | 2006-05-18 |
| ZA200700252B (en) | 2009-05-27 |
| EA200700909A1 (ru) | 2007-12-28 |
| MX2007005649A (es) | 2007-07-09 |
| DE102004054634A1 (de) | 2006-05-18 |
| JP2008519797A (ja) | 2008-06-12 |
| CA2575668A1 (en) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072601L (no) | Azaindolkarboksamider | |
| DK2023918T3 (da) | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser | |
| NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| NO20083562L (no) | Cannabinoidreseptormodulatorer | |
| NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
| NO20052796L (no) | Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| ATE509917T1 (de) | Gamma-secretase-inhibitoren | |
| NO20084328L (no) | Nye forbindelser | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| HUP0301513A2 (hu) | O-Aril-glükozid SGLT2 inhibitorok és eljárás elżállításukra | |
| NO20062704L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
| NO20081942L (no) | Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser | |
| WO2005013892A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| NO20073416L (no) | Indoler nyttig i behandlingen av inflammasjon | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| NO20081804L (no) | Pyrazolforbindelser egnet til behandling av inflammasjon | |
| NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
| ECSP055844A (es) | Nuevos compuestos triciclicos | |
| NO20081888L (no) | Triazolforbindelser som lipoksygenaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |